Drug Trial Radar · NCT05927571
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Aug 10, 2023
Primary completion
Jul 31, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jul 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.
Conditions
- Relapsed or Refractory Multiple Myeloma
Interventions
CevostamabDrug
Cevostamab solution for infusion will be administered as IV as specified in each treatment arm.
ElranatamabDrug
Elranatamab solution for injection will be administered SC as specified in each treatment arm.
TocilizumabDrug
Tocilizumab will be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: From signing of informed consent up to end of study (EOS) (approximately 36 months)
- Recommended Phase II Regimen (RP2R)Time frame: Up to approximately 36 months
Locations
14 sites in 3 countries. Site status is shown where the registry gives one.
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia · Recruiting
Calvary Mater Newcastle
Waratah, New South Wales, Australia · Recruiting
Royal Adelaide Hospital;Haematology Clinical Trials Unit
Adelaide, South Australia, Australia · Recruiting
St. Vincent's Hospital Melbourne
Melbourne, Victoria, Australia · Recruiting
The Alfred Hospital
Prahan, Victoria, Australia · Recruiting
Rambam Health Care Campus
Haifa, Israel · Recruiting
Hadassah University Hospital - Ein Kerem
Jerusalem, Israel · Recruiting
Tel Aviv Sourasky Medical Center PPDS
Tel Aviv, Israel · Recruiting
The Chaim Sheba Medical Center - PPDS
Ramat Gan, Central District, Israel · Recruiting
The Catholic University of Korea - Seoul St. Mary's Hospital (Kangnam St. Mary's Hospital)
Seocho, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Severance Hospital, Yonsei University Health System
Seoul, South Korea · Recruiting
Asan Medical Center.
Seoul, South Korea · Recruiting
Samsung Medical Center - PPDS
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.